Search





Search





Mereo BioPharma Group PLC

MREO

Add to Watchlist

0.330USD

+0.058+21.15%

Market hours （ET）Quotes delayed by 15 min

263.37MMarket Cap

LossP/E TTM

Mereo BioPharma Group PLC

0.330

+0.058+21.15%

Financial Summary Income Statement Balance Sheet Cash Flow Statement Earnings Company Valuation Risk Assessment

Overview

News&Analysis

Financials

Stock Score

Technical

Forecast

Ownership

Dividends

Profile

Discussions

Financial Summary Income Statement Balance Sheet Cash Flow Statement Earnings Company Valuation Risk Assessment

MREO Cash Flow Statement

You can access the annual and quarterly cash flow statements of Mereo BioPharma Group PLC to evaluate its financial soundness and stability.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023H1

FY2022H2

FY2022H1

FY2021H2

FY2021H1

FY2020H2

FY2020H1

FY2019H2

FY2019H1

FY2018H2

FY2018H1

FY2017H2

FY2017H1

FY2016H2

FY2016H1

Operating cash flows (indirect method)

Cash flow from continuing operating activities

48.23%-4.31M

18.45%-7.68M

2.79%-7.31M

3.20%-7.65M

-4.23%-8.33M

---9.42M

---7.52M

---7.90M

---7.99M

30.85%-16.72M

-10.93%-22.89M

-275.98%-24.18M

18.95%-20.63M

193.21%13.74M

-7.31%-25.46M

59.94%-14.74M

-110.93%-23.72M

-69.36%-36.79M

57.67%-11.25M

-53.38%-21.73M

-10.95%-26.57M

6.10%-14.17M

---23.95M

---15.09M

Net income from continuing operations

----

43.00%-14.71M

-518.34%-19.02M

-270.63%-25.81M

108.63%4.55M

109.52%15.13M

-86.46%-52.68M

-557.60%-158.86M

-21.61%-28.26M

9.19%-24.16M

10.34%-23.23M

22.50%-26.60M

-20.67%-25.91M

-41.72%-34.33M

---21.48M

---24.22M

Operating gains losses

-36.67%171.00K

67.88%460.00K

-86.17%39.00K

-36.96%162.00K

-1.82%270.00K

--274.00K

--282.00K

--257.00K

--275.00K

-11.98%497.96K

-34.36%341.72K

56.84%565.75K

-31.38%520.57K

-71.87%360.71K

-29.36%758.62K

36.95%1.28M

4615.38%1.07M

3273.35%936.48K

-7.12%22.78K

26.33%27.76K

17.94%24.52K

-7.93%21.97K

--20.79K

--23.87K

Other non-cash items

-164.33%-1.51M

99.43%-36.00K

-135.36%-2.42M

751.91%5.56M

1523.64%2.35M

---6.37M

--6.84M

--653.00K

---165.00K

207.23%3.16M

177.16%301.80K

-117.38%-2.95M

65.92%-391.11K

607.14%16.98M

-57.35%-1.15M

144.17%2.40M

9.08%-729.41K

-1111.80%-5.44M

-128.84%-802.29K

-33.64%537.25K

199.39%2.78M

-41.26%809.58K

---2.80M

--1.38M

Change in working capital

520.43%2.16M

-362.08%-2.25M

128.96%400.00K

-150.75%-843.00K

65.87%-514.00K

--857.00K

---1.38M

--1.66M

---1.51M

-456.82%-7.85M

-88.77%147.96K

156.38%2.20M

113.82%1.32M

20.23%-3.90M

186.85%616.30K

46.75%-4.89M

-199.65%-709.59K

-459.62%-9.18M

110.92%712.05K

-74.52%2.55M

-69.55%-6.52M

582.65%10.02M

---3.84M

--1.47M

-Change in receivables

----

-1684.42%-6.81M

-71.12%427.45K

118.48%429.50K

63.32%1.48M

-233.56%-2.32M

31.46%906.17K

63.68%-696.66K

538.02%689.32K

-293.58%-1.92M

196.02%108.04K

204.41%990.82K

78.29%-112.52K

18.60%-948.95K

---518.23K

---1.17M

-Change in prepaid expenses

201.12%271.00K

-83.97%235.00K

-118.85%-164.00K

108.73%113.00K

-113.82%-268.00K

--1.47M

--870.00K

---1.29M

--1.94M

----

-Change in payables and accrued expense

----

-158.92%-1.04M

-72.34%-279.49K

212.20%1.77M

44.06%-162.17K

---1.58M

---289.87K

----

-Change in other current liabilities

-109.98%-95.00K

17.88%-473.00K

834.96%1.66M

-101.08%-744.00K

299.58%952.00K

---576.00K

---226.00K

---370.00K

---477.00K

----

Cash from non-recurring investing activities

Cash from operating activities

48.23%-4.31M

18.45%-7.68M

2.79%-7.31M

3.20%-7.65M

-4.23%-8.33M

---9.42M

---7.52M

---7.90M

---7.99M

30.85%-16.72M

-10.93%-22.89M

-275.98%-24.18M

18.95%-20.63M

193.21%13.74M

-7.31%-25.46M

59.94%-14.74M

-110.93%-23.72M

-69.36%-36.79M

57.67%-11.25M

-53.38%-21.73M

-10.95%-26.57M

6.10%-14.17M

---23.95M

---15.09M

Investing cash flow

Net cash from continuing investing activities

-6.25%300.00K

--0.00

---300.00K

--0.00

-54.29%320.00K

--0.00

----

--700.00K

121.72%415.38K

-100.00%0.00

---1.91M

101.11%575.08K

100.00%0.00

981.23%285.95K

---2.55M

40.58%26.45K

-100.00%0.00

-99.37%18.81K

73.47%25.89K

243725.98%3.01M

685.69%14.92K

--1.23K

--1.90K

Capital expenditures

-6.25%300.00K

--0.00

-54.29%320.00K

--0.00

----

--700.00K

3101.18%415.38K

-100.00%0.00

--12.98K

154.96%729.07K

--0.00

981.23%285.95K

--0.00

30.85%26.45K

-100.00%0.00

-99.33%20.21K

83.46%27.38K

109974.57%3.01M

685.69%14.92K

--2.73K

--1.90K

Net cash flow from disposal of fixed assets

-100.00%0.00

--0.00

--20.00K

----

-100.00%0.00

--12.98K

154.96%729.07K

100.00%0.00

981.23%285.95K

---74.33K

30.85%26.45K

-100.00%0.00

313.95%20.21K

83.46%27.38K

78.58%4.88K

685.69%14.92K

--2.73K

--1.90K

Net cash flow from intangible asset transactions

0.00%300.00K

--0.00

---300.00K

--0.00

-57.14%300.00K

--0.00

----

--700.00K

121.57%415.38K

----

---1.93M

---153.99K

100.00%0.00

----

---2.48M

100.00%0.00

-100.05%-1.40K

---1.49K

200438.04%3.00M

--0.00

---1.50K

----

Net cash flow from business transactions

----

--0.00

100.00%0.00

-103.42%-445.97K

---374.04

--13.03M

----

Net cash flow from investment products

----

--0.00

-100.00%0.00

--11.30M

--30.89M

100.00%0.00

--0.00

---3.29M

----

Net cash flow from other investing activities

--0.00

--300.00K

----

--1.00K

----

100.00%0.00

--0.00

---873.27K

----

---1.21K

----

Cash from non-current investing activities

Net cash flow from investing activities

6.25%-300.00K

--0.00

--300.00K

-100.00%0.00

54.29%-320.00K

--0.00

--1.00K

---700.00K

-139.96%-415.38K

100.00%0.00

--1.04M

-101.11%-575.08K

-100.00%0.00

-102.54%-285.95K

-95.21%2.10M

60024.22%11.27M

169764.16%43.92M

99.70%-18.81K

-73.47%-25.89K

-510645.28%-6.30M

-685.69%-14.92K

---1.23K

---1.90K

Financing cash flow

Cash flow from continuous financing activities

-100.00%0.00

197.50%39.00K

100.00%0.00

-100.29%-134.00K

--422.00K

---40.00K

---594.00K

--46.78M

--0.00

52.83%-178.72K

-19.09%-577.76K

-100.35%-378.89K

97.03%-485.14K

71.35%108.22M

-802.09%-16.32M

2026.99%63.16M

-144.62%-1.81M

-1770.73%-3.28M

-102.31%-739.46K

-98.40%196.18K

25597.88%32.02M

-87.47%12.29M

---125.60K

--98.13M

Net cash flow from debt Issuance/repayment

----

--0.00

51.76%-278.56K

-5.46%-577.76K

-43.52%-577.42K

96.62%-547.83K

-100.91%-402.33K

-796.44%-16.21M

4482.01%43.97M

-407.14%-1.81M

---1.00M

-97.77%588.81K

--0.00

--26.36M

-100.00%0.00

--0.00

--4.96M

Net cash flow from common stock issuance/repurchase

----

--39.00K

--0.00

----

--0.00

--47.00M

----

--2.47K

----

--0.00

329.49%108.95M

-100.00%0.00

--25.37M

-100.00%5.04

-100.00%0.00

--158.96K

-98.91%206.50K

--0.00

-80.61%18.87M

--0.00

--97.32M

Proceeds from stock option exercised by employees

----

--62.69K

----

Proceeds from issuance of warrants

-100.00%0.00

--0.00

--487.00K

----

Net cash flow from other financing activities

100.00%0.00

38.81%-134.00K

---65.00K

---40.00K

---594.00K

---219.00K

----

-50.95%97.37K

--0.00

161.15%198.53K

100.00%0.00

94.75%-324.64K

-27166.34%-105.76K

-528.21%-6.18M

99.96%-387.89

-9427.23%-983.64K

-119.24%-1.09M

99.84%-10.32K

4611.97%5.67M

-58.39%-6.58M

---125.60K

---4.15M

Net cash from non-recurrent financing activities

Net cash from financing activities

-100.00%0.00

197.50%39.00K

100.00%0.00

-100.29%-134.00K

--422.00K

---40.00K

---594.00K

--46.78M

--0.00

52.83%-178.72K

-19.09%-577.76K

-100.35%-378.89K

97.03%-485.14K

71.35%108.22M

-802.09%-16.32M

2026.99%63.16M

-144.62%-1.81M

-1770.73%-3.28M

-102.31%-739.46K

-98.40%196.18K

25597.88%32.02M

-87.47%12.29M

---125.60K

--98.13M

Net cash flow

Beginning cash balance

-41.27%40.99M

-39.52%48.70M

-35.81%56.13M

28.41%62.48M

21.56%69.80M

--80.52M

--87.43M

--48.66M

--57.42M

-37.66%71.57M

-37.94%92.44M

253.78%114.80M

91.71%148.95M

60.10%32.45M

107.12%77.69M

-36.23%20.27M

-14.56%37.51M

-51.91%31.79M

-37.61%43.90M

-5.29%66.09M

-18.72%70.36M

328.20%69.79M

--86.57M

--16.30M

Current period cash flow changes

34.84%-4.77M

28.12%-7.71M

-7.50%-7.43M

-116.40%-6.36M

16.46%-7.32M

---10.72M

---6.91M

--38.77M

---8.76M

24.45%-17.53M

-9.54%-23.58M

-119.31%-23.20M

50.57%-21.53M

135.69%120.18M

-189.55%-43.55M

1114.20%50.99M

-24.03%-15.04M

119.54%4.20M

-353.09%-12.13M

-1037.18%-21.49M

87.37%-2.68M

-102.28%-1.89M

---21.19M

--83.04M

Effect of exchange rate changes

-117.29%-157.00K

95.00%-63.00K

-134.72%-418.00K

1433.64%1.43M

1397.14%908.00K

---1.26M

--1.20M

---107.00K

---70.00K

-168.02%-214.47K

-169.22%-115.08K

117.66%315.31K

111.18%166.26K

-483.05%-1.79M

-90.55%-1.49M

33.15%466.12K

-547.34%-780.48K

416.54%350.08K

93.39%-120.57K

--67.77K

-163.16%-1.82M

----

--2.89M

----

Ending cash balance

-42.03%36.22M

-41.27%40.99M

-39.52%48.70M

-35.81%56.13M

28.41%62.48M

--69.80M

--80.52M

--87.43M

--48.66M

-42.49%53.50M

-46.58%68.15M

-38.88%93.03M

297.56%127.57M

116.07%152.23M

48.05%32.09M

96.20%70.45M

-32.15%21.67M

-20.99%35.91M

-52.76%31.95M

-32.99%45.45M

2.31%67.62M

-27.36%67.83M

--66.09M

--93.38M

Free cash flow

46.68%-4.61M

18.45%-7.68M

2.79%-7.31M

3.20%-7.65M

0.48%-8.65M

---9.42M

---7.52M

---7.90M

---8.69M

29.17%-17.14M

-7.14%-22.89M

-276.08%-24.19M

17.02%-21.36M

193.21%13.74M

-8.39%-25.74M

59.94%-14.74M

-110.79%-23.75M

-69.15%-36.79M

61.91%-11.27M

-53.41%-21.75M

-23.50%-29.58M

6.01%-14.18M

---23.95M

---15.09M

Currency unit

--USD

Audit opinions

----

FAQs

What is operating cash flow?



Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did Mereo BioPharma Group PLC Generate?



Mereo BioPharma Group PLC generated -30.97M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did Mereo BioPharma Group PLC's Operating Cash Flow Change Year Over Year?



Mereo BioPharma Group PLC's operating cash flow increased by 5.67% year over year.

What is investing cash flow?



Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does Mereo BioPharma Group PLC Spend on Capital Expenditures?



Mereo BioPharma Group PLC spent 320.00K on capital expenditures in the most recent quarter。

What is financing cash flow?



Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has Mereo BioPharma Group PLC's Financing Cash Flow Changed?



Mereo BioPharma Group PLC used 327.00K in financing activities in the latest quarter.

What is free cash flow and why does it matter for MREO?



Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was Mereo BioPharma Group PLC’s free cash flow in the latest quarter?



Free cash flow was -31.29M reflecting a 6.69% change from the previous year.